Review of diphtheria, tetanus and pertussis vaccines in clinical development

Expert Review of Vaccines

Volumn 10, Issue 5, 2011, Pages 605-615

  Kitchin, Nicholas R E ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

acellular pertussis; combination; diphtheria; Haemophilus influenzae type b; hepatitis B; inactivated poliovirus; tetanus; vaccine; whole cell pertussis

Indexed keywords

COMBACT HIB; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; EASYSIX; GSK 2197870 A; GSK 2202083 A; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEXAXIM; LBVF 0101; LBVW 0101; MENINGOCOCCUS VACCINE; PENTACEL; PENTAXIM; PERTUSSIS VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; RECOMBINANT HEPATITIS B VACCINE; ROTAVIRUS VACCINE; SHANTETRA; TETANUS TOXOID; TETRABHAY; TRITANRIX HB; TRITANRIX HEP B HIB; UNCLASSIFIED DRUG;

DIPHTHERIA; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; INJECTION SITE REACTION; MENINGOCOCCOSIS; NONHUMAN; PERTUSSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; ROTAVIRUS INFECTION; SEROCONVERSION; TETANUS;

BIOMEDICAL RESEARCH; DIPHTHERIA TOXOID; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; PERTUSSIS VACCINE; POLIOVIRUS VACCINES; TETANUS TOXOID; VACCINES, COMBINED;

EID: 79957605492     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.60     Document Type: Review

References (18)

1. Tregnaghi MW, Voelker R, Santos-Lima E, Zambrano B. Immunogenicity and safety of a novel yeast Hansenula polymorphaderived recombinant hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. Vaccine 28(20), 3595-3601 (2010).
2. Tregnaghi MW, Zambrano B, Santos- Lima E. Phase I results of an investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine used as a booster dose in healthy Argentinean 16 to 19 month-old toddlers. Presented at: XIII La Sociedad Latino'a de Infectología Pediátrica (SLIPE). Guayaquil, Ecuador, 12-15 August 2009.
3. Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheriatetanus- acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr. Infect. Dis. J. DOI: 10.1097/INF.0b013e318212eb80 (2011) (Epub ahead of print).
4. Macías M, Lanata C, Zambrano B, Santos-Lima E. Safety and immunogenicity of an investigational hexavalent DTaP- IPV-Hep B-PRP-T vaccine at 2, 4, 6 months compared to licensed vaccines in Latin America. Presented at: 6th World Congress of the World Society for Pediatric Infectious Diseases. Buenos Aires, Argentina, 18-22 November 2009.
5. Madhi SA, Mitha I, Cutland C, Groome M, Santos-Lima E. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr. Infect. Dis. J. 30(4), e68-e74 (2011).
6. Ceyhan C, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent fully liquid DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim™) given at 2, 3, 4 months of age and as a booster at 15-18 months compared to licensed vaccines in Turkish infants. Presented at: 5th Asian Congress of Pediatric Infectious Diseases. Taipei, Taiwan, 23-26 September 2010.
7. Kosalaraska P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int. J. Infect. Dis. 15(4), e249-e256 (2011).
8. Halperin SA, Langley JM, Hesley TM et al. Safety and immunogenicity of two formulations of a hexavalent diphtheria- tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children. Hum. Vaccin. 1(6), 245-250 (2005).
9. Halperin SA, Tapiéro B, Diaz-Mitoma F et al. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis- inactivated poliovirus- Haemophilus influenzae b conjugate- hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. Vaccine 27(19), 2540-2547 (2009).
10. Diaz-Mitoma F, Halperin S, Tapiéro B et al. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 4, 6 and 12-14 months of age. Vaccine 29(6), 1324-1331 (2011).
11. Tapiéro B, Halperin S, Dionne M et al. Safety & immunogenicity of a novel hexavalent DTaP-IPV-Hib-HepB vaccine given at 2, 4, and 6 months of age. Presented at: Joint 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Infectious Disease Society of America (IDSA) Meeting. Washington DC, USA, 25-28 October 2008.
12. Tapiéro B, Halperin S, Dionne M et al. Safety and immunogenicity of a toddler dose of a liquid hexavalent DTaP-IPV-Hib-HepB vaccine following primary series. Presented at: 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Nice, France, 4-8 May 2010.
13. Tapiéro B, Halperin S, Dionne M et al. Safety & immunogenicity of a hexavalent DTaP5-IPV-Hib-HepB vaccine given at 2, 4,6 and 15 months of age. Presented at: 26th International Pediatric Association Congress of Pediatrics (IPA). Johannesburg, South Africa, 4-9 August 2010.
14. Knuf M, Schmitt HJ, Wolter J et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J. Pediatr. 152(5), 655-660 (2008).
15. Knuf M, Schmitt HJ, Jacquet JM et al. Booster vaccination after neonatal priming with acellular pertussis vaccine. J. Pediatr. 156(4), 675-678 (2010).
16. Wood N, McIntyre P, Marshall H, Roberton D. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr. Infect. Dis. J. 29(3), 209-215 (2010).
17. Mielcarek N, Debrie AS, Raze D et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2(7), e65 (2006).
18. Developing Countries Vaccine Manufacturers Network (DCVMN) Directory 2010. 19 Zorzeto TQ, Higashi HG, da Silva MT et al. Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants. Clin. Vaccine Immunol. 16(4), 544-550 (2009).